Immunocore Holdings plc

Radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases by pioneering and delivering transformative immunomodulating medicines.

• Proprietary Technology Platform — Utilizes the ImmTAX technology to activate or suppress the immune system to target diseased cells. [2], - End-to-End Drug Development — Manages the entire journey from lab bench to patient bedside, including clinical trials and commercialization. [2], - Diverse Pipeline Strategy — Develops multiple bispecific T cell receptor therapies across cancer, infectious, and autoimmune diseases. [2]

• KIMMTRAK vs. Standard of Care — KIMMTRAK doubles the likelihood of being alive at five years for first-line HLA-A*02:01+ patients with metastatic uveal melanoma. [3], - Tebe ntafusp vs. Other Melanoma Therapies — Tebentafusp is in Phase 3 trials for advanced cutaneous melanoma, competing with existing immunotherapies. [1], - ImmTAX Platform vs. Other Immunotherapies — ImmTAX offers a unique approach to activating or suppressing the immune system. [2]

• Limited Treatment Options — Patients with metastatic uveal melanoma and advanced cutaneous melanoma have limited effective treatments. [1], - Unmet Needs in Infectious Diseases — Lack of functional cures for HIV and Hepatitis B. [1], - Autoimmune Disease Management — Need for more effective treatments for type 1 diabetes and atopic dermatitis. [2]

Immunocore's focus on TCR therapies positions it at the forefront of immunotherapy innovation. The success of KIMMTRAK and the pipeline's progression are critical for future growth. The company's diverse pipeline across cancer, infectious diseases, and autoimmune conditions mitigates risk and opens multiple revenue streams. Regulatory approvals and commercial success of KIMMTRAK will be key indicators of the company's ability to scale and expand its market presence.

Expand commercialization efforts for KIMMTRAK in international markets to increase revenue. Accelerate clinical development of pipeline therapies to bring new products to market sooner. Strengthen partnerships with research institutions and healthcare providers to enhance clinical trial recruitment and data collection. Develop patient support programs to improve adherence and outcomes for patients receiving KIMMTRAK.